# US 8,541,577 B2 · Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,577 B2
- Document ID: US8541577B2
- Status: Granted
- Kind: B2
- Application number: 13/668,835
- Filed: 2012-11-05
- Published: 2013-05-16
- Granted: 2013-09-24
- Earliest claimed: 2011-11-10
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Richard L. Beard; Tien T. Duong; John E. Donello; Veena Viswanath; Michael E. Garst
- Web page: https://patentgrep.com/patent/US8541577B2

## CPC

- C07C 275/30: being further substituted by halogen atoms, or by nitro or nitroso groups
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 323/44: X or Y being nitrogen atoms
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 213/55: Acids; Esters
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 239/84: Nitrogen atoms
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel aryl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

## Claims

### Claim 1

A compound selected from:
or enantiomers, diastereomers, tautomers, hydrates, solvates, zwitterions or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein the compound is selected from:
(2S,3S)-2-({[(4-Bromo-2-fluorophenyl)amino]carbonyl}amino)-3-methylpentanoic acid;
(2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)pentanoic acid;
(2S)-4-methyl-2-{[({4-[(trifluoromethyl)thio]phenyl}amino)carbonyl]amino}pentanoic acid;
(2S)-4-methyl-2-[({[4-(trifluoromethyl)phenyl]amino}carbonyl)amino]-pentanoic acid;
(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}pentanoic acid;
(2S,3S)-2-({[(4-bromo-2-fluorophenyl)amino]carbonyl}amino)-3-methylpentan-amide; and
(2S)-2-({[(4-bromo-2-fluorophenyl)amino]carbonyl}amino)pentanamide.

### Claim 3 (depends on 1)

A compound according to claim 1 selected from:
(2S,3S)-2-({[(4-bromo-2-fluorophenyl)amino]carbonyl}amino)-3-methylpentanamide and
(2S)-2-({[(4-bromo-2-fluorophenyl)amino]carbonyl}amino)pentanamide.